Recently, several promising plasma biomarkers have been studied in a number clinical cohorts, such as plasma the Aβ42/40 ratio,7, 8, 9 NfL,10,11 GFAP,12, 13, 14 or different pTau isoforms, such as pTau181, pTau217, or pTau231.15, 16, 17 Various studies have shown that plasma pTau isoforms are highly accurate and specific for the detection of tau pathology and PET-confirmed amyloidosis across the clinical continuum of AD.18, 19, 20 However, the most widely studied CSF/PET reference of tau phosphorylation in the AT(N) classification is the pTau181 isoform.6 The gene discussed is MAPT; the disease is amyloidosis.